DelveInsight’s “Propionic Acidemia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Propionic Acidemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers the emerging Propionic Acidemia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Propionic Acidemia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Propionic Acidemia: An Overview
Propionic Acidemia is a rare metabolic disorder characterized by the deficiency of propionyl-CoA carboxylase, an enzyme involved in the breakdown (catabolism) of the chemical “building blocks” (amino acids) of proteins. Propionic acidemia affects about 1/20,000 to 1/250,000 individuals in various regions of the world.
Symptoms most commonly become apparent during the first weeks of life and may include abnormally diminished muscle tone (hypotonia), poor feeding, vomiting, listlessness (lethargy), dehydration, and seizures. Individuals with this condition have to follow a specific diet, including a low protein intake and specific food formulas (medical foods). A liver transplant is a surgical option that can help decrease the frequency of acute metabolic episodes (decompensation).
Propionic Acidemia Market Key Facts
According to Almási et al. (2019), In North America, detection rates of PA were 0.20 (US, California) per 100,000 newborns. The pooled point estimate indicated a detection rate of 0.33 per 100,000 newborns in North America.
According to Shchelochkov et al. (2016), worldwide, the cases of Propionic Acidemia (PA) vary widely. The estimated live-birth cases of PA are 1:105,000-1:130,000 in the US, 1:166,000 in Italy, and 1:250,000 in Germany.
According to Orphanet data, the prevalence rate of PA is probably about 1 in 100,000 live births worldwide.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Propionic Acidemia market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Propionic Acidemia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Propionic Acidemia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Propionic Acidemia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Propionic Acidemia Epidemiology, Segmented as –
Total Prevalent cases of Propionic Acidemia in the 7MM [2019–2032]
Total Diagnosed Prevalent Cases of Propionic Acidemia in the 7MM [2019–2032]
Severity-specific cases of Propionic Acidemia in the 7MM [2019–2032]
Treatable cases of Propionic Acidemia in the 7MM [2019–2032]
Propionic Acidemia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Propionic Acidemia market or expected to be launched during the study period. The analysis covers the Propionic Acidemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the Propionic Acidemia market drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the Propionic Acidemia drugs based on their sale and market share.
The report also covers the Propionic Acidemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Propionic Acidemia Market Will Evolve and Grow by 2032 @
Propionic Acidemia Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Propionic Acidemia. Currently, Moderna is leading the therapeutics market with its Propionic Acidemia drug candidates in the most advanced stage of clinical development.
Propionic Acidemia Companies Actively Working in the Therapeutics Market Include
CoA Therapeutics, Inc.
And Many Others
Emerging and Marketed Propionic Acidemia Therapies Covered in the Report Include:
HST 5040: HemoShear Therapeutics
BCAT2 inhibitors: Agios Pharmaceuticals
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Propionic Acidemia Competitive Intelligence Analysis
4. Propionic Acidemia Market Overview at a Glance
5. Propionic Acidemia Disease Background and Overview
6. Propionic Acidemia Patient Journey
7. Propionic Acidemia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Propionic Acidemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Propionic Acidemia Unmet Needs
10. Key Endpoints of Propionic Acidemia Treatment
11. Propionic Acidemia Marketed Therapies
12. Propionic Acidemia Emerging Drugs and Latest Therapeutic Advances
13. Propionic Acidemia Seven Major Market Analysis
14. Attribute Analysis
15. Propionic Acidemia Market Outlook (In US, EU5, and Japan)
16. Propionic Acidemia Access and Reimbursement Overview
17. KOL Views on the Propionic Acidemia Market
18. Propionic Acidemia Market Drivers
19. Propionic Acidemia Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Point of Care Glucose Testing Market
“Point of Care Glucose Testing Market Insight, Competitive Landscape, and Market Forecast, 2028” report delivers an in-depth understanding of historical and forecasted Point of Care Glucose Testing market size, share, and trends globally, which comprises North America, Europe, APAC, and RoW. Moreover, it covers the key companies, emerging products, and commercial & regulatory development, in the Point of Care Glucose Testing Market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States